Trial Profile

A Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase 2, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enavogliflozin (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Daewoong Pharmaceutical

Most Recent Events

20 Jul 2023 Status changed from recruiting to completed.
20 Jul 2023 Results (n=194) assessing the efficacy and safety of enavogliflozin in Korean patients with type 2 diabetes mellitus published in the Diabetes, Obesity and Metabolism
29 Sep 2020 Primary endpoint(Change from baseline in HbA1c) has been met, according to a Daewoong Pharmaceutical Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com